Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG

References

• Larsen MJ, Thomassen M, Gerdes AM, et al. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl). 2014;8:145–155.
   PubMedGoogle Scholar
• Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997;33:362–371.
   PubMed Web of Science ®Google Scholar
• Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 1998;83:2335–2345.
   PubMed Web of Science ®Google Scholar
• Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134–147.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138–1145.
   PubMedGoogle Scholar
• Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012;30:19–26.
   PubMed Web of Science ®Google Scholar
• Jonasson JG, Stefansson OA, Johannsson OT, et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer. 2016;115:776–783.
   PubMed Web of Science ®Google Scholar
• Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016;22:3971–3981.
   PubMed Web of Science ®Google Scholar
• Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39:22–25.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. J Clin Epidemiol. 2015;7:449–490.
   PubMed Web of Science ®Google Scholar
• Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health. 2011;39:72–74.
   PubMed Web of Science ®Google Scholar
• Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39:42–45.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Ejlertsen B, Jensen MB, et al. Danish Breast Cancer Cooperative Group. J Clin Epidemiol. 2016;8:445–449.
   PubMed Web of Science ®Google Scholar
• Danish Breast Cancer Group Guideline. hereditary Breast- and Ovarian Cancer. 2016. [Internet]. Available from: http://dbcg.dk/PDF%20Filer/Kapitel_19_HBOC_23.09.2016.pdf
   Google Scholar
• Thomassen M, Hansen TV, Borg A, et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol. 2008;47:772–777.
   PubMed Web of Science ®Google Scholar
• Danish Breast Cancer Group Guideline. Clinical guidelines, DBCG. Copenhagen, Denmark: DBCG; 2017.
   Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.
   PubMed Web of Science ®Google Scholar
• Eckhoff L, Nielsen M, Moeller S, et al. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol. 2011;50:1075–1082.
   PubMed Web of Science ®Google Scholar
• Jensen MB, Ejlertsen B, Mouridsen HT, et al. Improvements in breast cancer survival between 1995 and 2012 in Denmark: the importance of earlier diagnosis and adjuvant treatment. Acta Oncol. 2016;55(Suppl 2):24–35.
   PubMed Web of Science ®Google Scholar
• Pedersen IS, Schmidt AY, Bertelsen B, et al. A Danish national effort of BRCA1/2 variant classification. Acta Oncol. 2018.
   Web of Science ®Google Scholar
• DBCG retningslinjer/vejledninger: Patologi. Copenhagen, Denmark: DBCG. Available from: http://dbcg.dk/PDF%20Filer/Kap_3_Patologi_22_juni_2017.pdf
   Google Scholar
• Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359–377.
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Ellis IO, Schnitt SJ, et al, editors. WHO classification of tumours of the breast. 4th ed. Vol. 4. WHO/IARC; 2012.
   Google Scholar
• Ejlertsen B, Jensen MB, Mouridsen HT. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer. Acta Oncol. 2014;53:174–185.
   PubMed Web of Science ®Google Scholar
• Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444.
   PubMed Web of Science ®Google Scholar
• Gerdes AM, Cruger DG, Thomassen M, et al. Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families. Clin Genet. 2006;69:171–178.
   PubMed Web of Science ®Google Scholar
• Winter C, Nilsson MP, Olsson E, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016;27:1532–1538.
   PubMed Web of Science ®Google Scholar
• van den Broek AJ, Schmidt MK, van 't Veer LJ, et al. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis. PLoS One. 2015;10:e0120189.
   PubMed Web of Science ®Google Scholar
• Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat. 2010;119:13–24.
   PubMed Web of Science ®Google Scholar
• Huzarski T, Byrski T, Gronwald J, et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol. 2013;31:3191–3196
   PubMed Web of Science ®Google Scholar